Levomepromazine for schizophrenia

P Sivaraman; R Rattehalli; M Jayaram

Journal article

Levomepromazine for schizophrenia

P Sivaraman, R Rattehalli, M Jayaram

Schizophrenia Bulletin | Published : 2012

DOI: 10.1093/schbul/sbr174

Abstract

BACKGROUND: Levomepromazine is an 'older' typical antipsychotic medication licensed for use in schizophrenia but sparingly prescribed in the United Kingdom. OBJECTIVES: To determine the clinical effects and safety of levomepromazine compared with placebo or antipsychotic medications for schizophrenia and schizophreniform psychoses. SEARCH STRATEGY: We searched the Cochrane Schizophrenia Group's Register (December 2008) which is based on regular searches of, amongst others, BIOSIS, CENTRAL CINAHL, EMBASE, MEDLINE and PsycINFO. References of all identified studies were inspected for further trials. We also contacted relevant pharmaceutical companies for additional information. SELECTION CRITER..

View full abstract

University of Melbourne Researchers

Mahesh Jayaram Author

Grants

Funding Acknowledgements

[ "We would like to thank the Cochrane Schizophrenia Group's Editorial Base for their support throughout the development of the protocol and review.", "Internal sources", "Leeds Partnerships NHS Foundation Trust, UK." ]